Format

Send to

Choose Destination
Anatol J Cardiol. 2019 Sep;22(4):185-191. doi: 10.14744/AnatolJCardiol.2019.13367.

Assessment of subclinical atherosclerotic cardiovascular disease in patients with ankylosing spondylitis.

Author information

1
Department of Physical Medicine and Rehabilitation, Kahramanmaraş Afşin State Hospital; Kahramanmaraş-Turkey.
2
Department of Physical Medicine and Rehabilitation, Faculty of Medicine, İzmir Katip Çelebi University; İzmir-Turkey.
3
Department of Physical Medicine and Rehabilitation, İzmir Bozyaka Training and Research Hospital of University of Health Sciences, İzmir, Turkey.
4
Department of Radiology, İzmir Bozyaka Training and Research Hospital of University of Health Sciences, İzmir, Turkey.
5
Department of Biochemistry, İzmir Bozyaka Training and Research Hospital of University of Health Sciences, İzmir, Turkey.
6
Department of Nephrology, İzmir Bozyaka Training and Research Hospital of University of Health Sciences, İzmir, Turkey.

Abstract

OBJECTIVE:

The aim of the present study was to compare patients with ankylosing spondylitis (AS) with healthy controls with respect to subclinical atherosclerotic cardiovascular disease (CVD).

METHODS:

A total of 44 patients with AS with no history of CVD, diabetes mellitus, hypertension, chronic kidney disease, and lipid-lowering drug use were compared with 40 age- and sex-matched healthy controls with respect to carotid intima-media thickness (CIMT) and pulse wave velocity (PWV), which are surrogate markers of subclinical atherosclerosis. Correlation analysis was also performed to examine the association between surrogate markers and disease activity with inflammation [Ankylosing spondylitis disease activity score with C-reactive protein (ASDAS-CRP)].

RESULTS:

In addition to age and sex, both groups were comparable with respect to cigarette smoking, body mass index, and high-density lipoprotein cholesterol (p=0.425, p=0.325, and p=0.103, respectively). The level of total cholesterol was significantly lower in patients with AS (p=0.002). Nonsteroidal anti-inflammatory drug and tumor necrosis factor alpha inhibitor use ratios in patients with AS were 79.5% and 65.9%, respectively. There was no significant difference between both groups regarding PWV and CIMT (p=0.788 and p=0.253, respectively). In patients with AS, there was a significant correlation between ASDAS-CRP and CIMT (r=0.315, p=0.038), but the correlation between ASDAS-CRP and PWV was not significant (r=-0.183, p=0.234).

CONCLUSION:

The results of the present study could not provide sufficient evidence whether disease activity with inflammation caused subclinical atherosclerotic CVD in patients with AS without overt CVD. The increased atherosclerotic CVD risk is most probably multifactorial in patients with AS, but the extent of the contribution of disease activity with inflammation to increased atherosclerosis is controversial.

Free full text

Supplemental Content

Full text links

Icon for Kare Publishing
Loading ...
Support Center